NeuroMetrix, Inc., a healthcare company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, China, the Middle East, and Mexico. Its primary marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system, a platform for the performance of nerve conduction studies. The company offers its products to managed care organizations, endocrinologists, podiatrists, and primary care physicians; occupational health, primary care, internal medicine, orthopedic, and hand surgeons; and pain medicine physicians, neurologists, physical medicine and rehabilitation physicians, and neurosurgeons. NeuroMetrix, Inc. was incorporated in 1996 and is headquartered in Woburn, Massachusetts.
Depending on the exchange, the stock ticker may vary. For instance, on Boerse Stuttgart exchange Neurometrix stocks are traded under the ticker NLZ.STU.
Does Neurometrix pay dividends?▼
Yes, NLZ.STU dividends are paid annual. The last dividend per share was 0.91 EUR. As of today, Dividend Yield (FWD)% is 0%.
How many employees does Neurometrix have?▼
As of September 04, 2026, the company has 13 employees.
In which sector is Neurometrix located?▼
Neurometrix operates in the Health & Wellness sector.
When did Neurometrix complete a stock split?▼
The last stock split for Neurometrix was on November 22, 2023 with a ratio of 1:8.
Where is Neurometrix headquartered?▼
Neurometrix is headquartered in Woburn, United States.